Back to top

crispr: Archive

Andrew Rocco

5 Reasons to be Bullish into 2024

Stock Strategist Andrew Rocco unveils 5 bullish undercurrents that will push stocks even higher into the new year.

NVOPositive Net Change NVDANegative Net Change QQQPositive Net Change IWMPositive Net Change KREPositive Net Change CRSPNegative Net Change METAPositive Net Change

Kevin Cook

Bull of the Day: CRISPR Therapeutics (CRSP)

FDA approval for revolutionary Sickle Cell Disease gene-editing treatment promises a bright future

CRSPNegative Net Change VRTXNegative Net Change EDITNegative Net Change

Zacks Equity Research

CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline

Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.

NVOPositive Net Change VRTXNegative Net Change CTMXPositive Net Change CRSPNegative Net Change